CR

Confident-Web-7118

Thank you for your comment. Remember this in AML CR2 (not eligible for transplant), and that both arms had the nasty treatments (chemo induction). If background frailty was the main killer, the control arm (BAT) survivors would be dying at the same rate. Instead, we see a massive divergence (about 71% alive on GPS vs. 10% on BAT). That gap can't be explained by general health, it can only be explained by the drug stopping the cancer. In REGAL, it doesn't matter if a patient dies from AML relapse, a heart attack, or frailty from past chemo. They all count as events. The 72 events we have observed so far already include those background deaths. If these patients were dying at an accelerated rate due to being "unhealthy," we would see it in the recent data. Instead, we saw only 12 deaths from Dec 2024/Jan 2025 to Dec 26th, 2025 across the whole study. That is a remarkably low death rate of about 1 per month. It proves that frailty isn't driving a mass die off. While these patients have been through nasty treatments, the risk of dying from AML relapse (which historically before GPS, kills 90% of patients within 2 years) is vastly higher than the risk of dying from run of the mill causes (maybe 3-5% per year). The "cure fraction" in the model is that transition point. The curve flattens out exactly when patients "stop dying" of AML (meaning stability) and return to the "normal" (realistically slightly elevated) mortality risk of their age group. The model doesn't predict immortality; it just predicts they "won't die" of leukemia.

Confident-Web-7118

You're numbers for patients is totally wrong here, respectfully. You said 220K customers? That is totally wrong. In the U.S., there are only about 5,000 to 8,000 patients available a year for Onureg, in CR1. If Onureg made $34M, and the net price is about $150k (after rebates), that means only 226 patients took the drug. Onureg is a commercial flop because of low adoption (doctors don't prescribe it), not because insurers refused to pay the unit price. Which obviously isn't the case. Onureg's annual revenue is not $34M like you said, it's conervatively based on SEC filings, $168M revenue and a conservative net price of $150k–$180k per patient (after insurance rebates), the actual number of patients on Onureg is about 1,000 patients, not 220,000. What you are sharing here is not correct at all, and will only confuse people.

all-cap-be

Ai gave me like 5 red flags for the post, first one: My Critical Red Flag Analysis 🚩 🚩 RED FLAG #1: Wildly Optimistic Projections Claim: GPS median OS = 97-183 months (8-15 years)[reddit] Reality check: • Historical AML CR2 patients: 8-11 months median OS • Even successful AML maintenance therapies extend this to 15-24 months • No AML therapy has ever achieved 8-15 year median OS in this population • This would be the greatest oncology breakthrough in decades • If true, GPS would be worth $50B+, not $500M market cap My assessment: This is fantasy-level projection that ignores oncology reality.

Confident-Web-7118

Thanks for your comment. I can expand on this but here is an overview in a concise way: GPS annual sales will be at least $4B and GPS + SLS-009 will be $6.5B to $8.5B.) GPS extends survival to 30-40+ months (as the REGAL data implies), thus LTV estimate is: ​$260K (Y1) + $100K (Y2) + $100K (Y3) + $50K (Y4/Tail) = $510K Total LTV. $510K ÷ 3.5 years = $145K annual revenue per patient. The most interesting thing is new transplant ineligible patients in the U.S. (not including globally): There's only about 3,000 new CR2 and 6,000 new CR1 patients each year. If everyone mostly died in 8 months (like they do now), revenue would be small ($260K × 9,000 = $2.3B max). Because GPS keeps patients alive for 3-4 years, by Year 4, you aren't just treating the new patients. You are treating: 2026 survivors (Year 3 of dosing) 2027 survivors (Year 2 of dosing) 2028 new starts (Year 1 of dosing) This is what creates the 27,000 patient pool and the $4.0B+ annual revenue 4 x 3 to 5 Peak Sales (standard for general acquisitions in Bio) is 20B for example, and this is a breakthrough in oncology. The floor really is 10B, but I just said 6B because I'm a deep value investor and always assume worst case scenarios. The range is that broad because we ultimately don't know what the bidding war between strategics like ABBV, BMS' etc. will lead to, as we're just talking about GPS here for AML CR2 and CR1. We haven't even discussed SLS-009 (which will be bigger than GPS) for the Frontline, which is in Phase 2B, we haven't talked about the other indications from the WT1 targeting that is present in 20+ cancers, etc.

Confident-Web-7118

Replying here so people don't get confused. First off, thank you for your comment, appreciate it. The peak revenue estimates I shared are correct. I think you're forgetting a few things: First is about Onureg (oral azacitidine). GPS had 1.5X the results of Onureg during Phase 2 in CR1, and this was before the unlimited dosing that occured later on in Phase 3 (right now). ​Price: Onureg is priced at roughly $24,000 - $28,000 per month (approx. $300,000+ per year). ​Second is tha insurance companies already pay about $300k/year for a drug (Onureg) that offers a 24-month median survival in CR1 (8 to 10 in CR2, if that). GPS offers 30+ months of survival in CR2, way above that in CR1, insurance cannot force a price of $50k. It would be priced at least at parity with the inferior standard of care. ​And third is orphan drug pricing power. GPS has Orphan Drug Designation. The median cost for orphan cancer drugs often exceeds $200,000 annually. A price tag of $50k/year would be suicidally low for a life-extending biologic in a fatal disease.

zaklikestuna

Yes, I purchased and reviewed the papers from the court website here - https://dja-prd-ecexap1.kingcounty.gov/?q=Home. 02/13/2026 08:30 AM Motion w/o Oral Argument ENTRY OF JUDGMENT CR 41(a)(1)(B) dismissal worked as intended, default judgement is very strong for this case.

Run4theRoses2

The recent Market Action is telling all who don't know or who aren't sure, - Gps is 100% for Sure Getting FDA Approval and that SLS is worth F Ton More than what shorts sold it Down for - What is GPS TRULY WORTH? Incoming Phase 3 Results for GPS Immunotherapy are offering a true Once in a Lifetime Investment Opportunity. $.64b Manipulated Market Cap worth $40B to Big Pharma the Instant the Phase 3 Results are Announced. **- The Value of a Positive Phase 3 Result exceeds $40B, more than 77x the current manipulated $.6b mcap. SLS Share Price will continue climbing until the P3 Results are released, and then it Launches.** \- Big Pharma's Pay 4X Revenue Multiples in buyouts. \- 12,500 AML CR2/CR3 Patients Each Year\* - current P3 Setting. SLS published est\* rev per patient of $280K /year. ​\*\*- $3.5B Year 1 TAM\*\* Currently 5-7,000 AML CR2 Patients Who Also Will Be Immediately Eligible for Gps Immunotherapy right out of the Gate upon approval: 5,000 \* $280k = $1.4B **Year 1 Total Addressable Market $4.9B** for Just for AML CR2/3 - the Setting for the Phase 3 Trial. AND THEN COMPOUND IT - Infinite Dosing to Until Relapse \- Year 1 Rev $280K Per Patient / 15 Doses - Year 2 Rev $112K Per Patient / 6 Doses \- Year 3+ Rev $70K Per Patient / 4 Doses the Ad Infinitum Dosing Regime Doubles the Total Addressable Market for AML CR2 CR3 Then Add AML CR1/ Post ASCT - 5X the SIZE of CR2/3 Esp w VIALE-M CR1 Trial Failing and VIALE-T P/Asct Failing. **You absolutely Know Big Pharma Will be Adding AML CR1 Patient and AML Post Asct Patient Populations to the Potential Revenue Calculations.**Gps will be Effective in over 20 different cancer settings that harbour WT1 +. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $abbv for $10.1B - this is just 1 comp worth $10B. \* Sources available upon request \-- ABVX was a $5 and change Equity prior to releasing its Phase 3 Trial Results - it launched on the P3 announcement - T1 Trading Halt and a Gap UP opening at $60 and it Kept on Climbing to a high of $145. \- buyout expected/

GorditoChiquitito

Honestly it was just an estimate because of the fact that the study has been ongoing for 22 months when AML CR2 patients have historically survived only 6-8 months. Although I hope the results continue to stay delayed so that the success can hopefully be linked to GPS, it was just a rough estimate. I hope I am extremely wrong & that the press does not release anything regarding the 80th event anytime soon :)

GorditoChiquitito

IMO the only realistic way “longer” could be negative is if the BAT arm is performing meaningfully better than expected, which would narrow the gap between the groups and make statistical significance harder to achieve. Although, the last patient in the REGAL trial was enrolled around March 2024, and as of today (February 2026) the study has been ongoing for roughly 22–23 months since that point. In AML CR2 patients who are ineligible for transplant, historical median survival is only 6–8 months with most survival events typically occurring within the first year. From a timing perspective the fact that this trial is still progressing nearly two years after the final enrollment places it well beyond what would normally be expected if outcomes were tracking historical BAT data, which is why the duration itself continues to draw attention. Those extra survival days have to be coming from one arm or the other. While short term delays can be explained by tail survivors in the control arm, those tails are historically limited in this population. As time goes on it becomes increasingly difficult to credit delays solely to BAT tail effects, making it more likely that GPS is contributing to the survival extension. This doesn’t guarantee success but it does make the “longer is bad” scenario less likely the longer the trial runs. I’m so glad that you are apart of the SLS community & thank you for opening up about your personal experience as a cancer survivor, perspectives like yours are why medicine like these matter on a human level, not just an investment one

GorditoChiquitito

I understand the point that you’re trying to make, although I think it’s important to separate trial results from human outcomes. No one is hoping patients die sooner, the reality is that survival trials end when enough events naturally occur, regardless of what investors want. If GPS proves effective and gets approved, it has the potential to help THOUSANDS of AML patients every year who currently have NO approved maintenance option in CR2. Unfortunately, every life saving cancer drug in existence required trials where patients still passed away due to the disease & that’s not because of greed, it’s because AML is aggressive and lethal even with treatment. The ethical goal of trials like REGAL is that the long-term lives saved vastly outweigh the unavoidable losses during development, and if GPS works, that’s exactly what would happen. There’s something truly gratifying about potentially being part (even as a shareholder) of a breakthrough that helps patients spend meaningful extra time with their families. This drug is about helping people with very very limited options. If the data comes out positive, not only is that good for the stock, but it’s genuinely uplifting because AML is such a devastating disease, it improves the quality of life during the process (unlike other alternatives) and genuinely will save countless lives. Some investors are in this not just for profit but also rooting for a win against cancer. Fuck cancer and let’s hope for the best results !!

Late-Tadpole-2318

Someone on my feed is saying this was the catalyst for yesterday’s sell off https://www.challengergray.com/wp-content/uploads/2026/02/CR126007123.pdf

hershculez

3.25% at my CR. No brick and mortar is doing 5% in a HYSA currently.

OsoOak

Well, CR7 is pretty like able

vegeful

Naah ain't no way CR7 is pedo.

Focux

CR7??

reaper527

> Should you buy RDDT? nope. over the next year digg is going to eat its lunch. their admins are just so responsive and friendly unlike spez+co. like, when they get a suggestion the answer is "we can do that, it will be rolled out tomorrow" https://digg.com/digg/oPmM9CR/comment/gzAyxVp between reddit getting actual competition for the first time ever, and the reality of the situation that ai search tools have lots of the major companies downgrading their rating of reddit (such as wells fargo recently), it seems pretty clear reddit's future is murky at best.

Reasonable_Roger

Because multiple members of the GOP caucus look for opportunities to piss on Trump's leg any chance they get these days? I don't know.. It's not the vote on the actual minibus+CR.. it's a vote on the rules for multiple bills for the week. Some GOP want to torpedo the bill with the SAVE act being attached, some don't want cave at all and want to pass the full 6-pack minibus, some just hate trump and want to cause trouble or bargain for some pork.. it's hard to say.

BoringAward2832

Yo what are some puts for tmr???? CR, GLD, GOOG lmk boys

BoringAward2832

CR lmk everyone

GrandGlacier1

CR. Retail also wins some, and loses some. As long as your overall returns are higher than the average market returns, that's the goal.

StormWhich5629

Good. I paid 60k in taxes this year, for what? Shut this shit the fuck down and primary every motherfucker who votes for any CR.

GrandGlacier1

CR If you look at the VIX index, aside from 2008 recession, VIX has been highest during Trump's terms

GrandGlacier1

CR plus market is so unstable. Trump tweets and healthcare tanks. It’s like we have to monitor the market daily if we’re not 100% in VT only. 

Prestigious_Ear_3737

True. 2 week reprieve...CR

Prestigious_Ear_3737

No they did not. They got a CR on DHS for 2 weeks.

tech01x

That's not what this means. The CR report is looking at vehicles that are already 5-10 years old. That's basically not the current vehicles and how they last. OTOH, CR looks at the last 2-4 years of data and ranks the Tesla Model 3 and Model Y as most reliable.

CarteBlanchDevereau

There's data for CR1 in the phase 1/2 trial. This trial is doing CR2 not as an indication, but as a test population. Whether or not they get CR1 at approval, or if they have to do a confirmation trial, I don't know. But it will (eventually) be for CR1 as well. More important than that, this drug targets WT1. And potentially it does so more effectively than any other medication. On top of that, the current generation of this drug is a four peptide variation, but GPS plus, is a seven peptide version that's showing even better data in its preclinical.

neo2551

Yes, the study is in CR2, but if it works for CR2, there is no reason FDA would not approve for CR1, as the population is more difficult in CR2.

Descendant3999

It is for CR2. Not all patients will have this treatment. You cannot just assume 100% market adoption lmao. You calculated TAM not the actual revenue

neo2551

It will go to 120$. The math: 150k patients/year (because 50k new CR1 cases per year, but they survive multiple years), 150k USD / patient, 8 years of patents, 12% discount values, \~72bn values, 217m shares. \~120$ / share. So the maths are not crazy. The question is how effective the drug is.

OkReception9095

I don’t use polymarket but i actually think “no” would be a good guess. I think sentiment on this shifts more and more through the week and Republicans looking to keep their seat in +15 and under districts break to pass a CR and negotiate on DHS.

Matwyen

The biggest grip I have with Metaverse is that the narrative was basically "yeaaah we will have Private property™, Rent of digital land© and Office work®" Marketing team fumbled on this one. Should they have gone with tight integration with Instagram, gave CR7 and other insta superstars content creator tools that allows for premium insta content, people would have flown to that. 

More_Advertising_383

IBRX short term swing trade / possible squeeze play. SLS is a pre-revenue biotech with 2 blood cancer therapies in the pipeline. First one should complete a successful phase 3 Regal trial by EOY and 5x-20x from here on a buyout due to patients living quite a bit longer than expected, followed by their second asset that had stellar phase 2 numbers to finish in ‘27-‘28. They treat CR1 and CR2 in AML and this would make them a platform therapy and easily 10b-20b market cap. They’re currently at 677m Transparency: I know worlds less about IBRX

Spiritual-Tailor9209

They have a vaccine for AML cancer called GPS.  It’s in phase 3 trial right now.  The trial is structured in a way that when 80 total deaths occur (in best available therapy group and GPS group) the trial ends.  There are over 120 patients in the trial.   Long term investors expected the trial to end early 2025.  Then the IDMC reviewed how the trial was going in January? 2025 and I believe this was they changed the protocol to allow much more dosing since there weren’t any real adverse reactions to GPS.  Phase 2 trials were phenomenal, and people theorized that will doctors giving much more doses of GPS in phase 3, it will likely work even better in phase 3.   Investors thought by October 2025 the 80th “event” would surely happen.  And if the 80th death happened in October the trial would surely exceed the necessary hazard ratio with flying colors.  People thought in October they must be at 79 deaths.  Then November and still the trial continues.  Then December.  Then the end of December they announce that they’re only at 72 FUCKING DEATHS.  Fucking insane.  At this rate the trial might not even finish this year.  For all we know there might not ever be 80 deaths until 8 more patients die of natural causes someday.   In which case the trial would be halted for efficacy at some point.  Also, the patients in the trial are CR2 patients which normally has a life expectancy with best available therapy (control group) of about 6-8 months.   The only real bear case has been that the best available therapy has gotten better recently, and it’s not actually 6-8 months life expectancy anymore.  It’s maybe 10 months now.  Let’s pretend that’s true (it’s not).  We obviously passed that point a long fucking time ago.   The other bear case is that the trial is a scam.  That bear case is for investors that know nothing about biotech, because Sellas has nothing to do with this trial so if it’s a giant scam then the scam is being done by the IDMC and the FDA lol.   In other words there is no real bear case.   The only bear case in my mind, although a giant stretch, is the trial ends, the drug is hugely successful, but no pharma company is willing to pay what SLS wants for a buyout, so SLS is forced to bring the drug to market an their own.  This would be bad, but the likelihood of this is virtually zero.   And I’m not an expert, I got in in late October.  Others here will know more than me.  Also, it was obvious to me that the longs for this stock are very smart people, which is always a good sign to me.  SLS discussions online tend to have much more in depth conversation and analysis compared to your typical stock.  

theepi_pillodu

so the first gen Chevy bolt, one of those Samsung phone, those hover boards etc weren't tested by CR before they were launched?

Happy_Discussion_536

>economic socialist and left ===> then proceed to cut off funding to social program, veteran benefit, early child hood food access, destroy renewable investment already underway. You either got infected by rfk brain worm or you have very loose definition on what's consider socialist and left. If you believe taco is economic socialist then you probably believe democratic republic of north korea is a democracy. If all it take is a title caption to mislead you. u/CoughRock That was his party in Congress. He even told them pass ACA subsidies. I hate the guy trust me. But his instinct is populist first. But he has to balance traditional economic conservatives in his base. His economic proposal had greater deficits than Kamala. He pushed for CR no cuts and running WW2 deficit currently. He obviously is not full on Sanders, duh. But he's way, way left of traditional right on fiscal policy. He's against fixing social security and medicare with reform. I'll put down remindme, just watch in a year he will continue advocating for massive budgets with huge spending and ally with socialists on numerous issues.

Happy_Discussion_536

CR

Happy_Discussion_536

That was GOP. He even told them pass ACA subsidies. I hate the guy trust me. But his instinct is populist first. But he has to balance traditional economic conservatives in his base. His economic proposal had greater deficits than Kamala. He pushed for clean CR no cuts and running WW2 deficit currently. He obviously is not full on Bernie, duh. But he's waayyyy left of traditional GOP on fiscal policy. He's against fixing SS and medicare with reform.

Theinternationalist

The President of the United States doesn't actually *have* the ability to add/cut budgets, most budgets for the last few decades are treated as more opening bids for Congress to either adjust or completely throw out. Sometimes the budget fails to get enough votes to pass- even when amended- and Congress passes a continuing resolution instead. For those who are wondering, the last government shutdown was because Congress failed to agree on a Continuing Resolution (CR), partially because Congress failed to get together to pass a budget that would have lasted all year.

BruceInc

The claim that FDA approval is “virtually certain” just isn’t supported by the facts. This write-up treats trading activity, short interest, borrow rates, and REG SHO as proof of efficacy or approvability. None of that has anything to do with whether a drug works or gets approved. REGAL is an event-driven Phase 3 trial in AML CR2 maintenance with overall survival as the primary endpoint. As of Dec 26, 2025, the CRO reported 72 events, with final analysis at 80 events, and the company has said it remains fully blinded to outcomes. Until that data reads out with a clear OS benefit, acceptable safety, and a clean regulatory package, FDA approval is speculation, not a conclusion. The TAM math is also misleading. Quoting 24,000 patients per year for “AML CR2” conflates total AML incidence with CR2 maintenance eligibility. About ~22,000 new AML cases per year is the entire AML population, not the much smaller subset that relapses, achieves CR2, and is eligible for maintenance. CR2 is a subset of a subset, and the true eligible pool is meaningfully smaller and variable, which materially impacts valuation. Bottom line: this reads like a hype post built on market mechanics and inflated assumptions, not a grounded biotech investment thesis. The real bull case here is simple: REGAL needs to show a statistically and clinically meaningful OS benefit. Everything else being cited is noise until that happens.

YoBee9

OK great, you are seeing the light. Drug will work or not. Now let's see your break down on company valuation. Inputs are: \-total target population \-annual treatment cost (150k - 200k is fair IMO based on what other similar treatments go for) \-market share assumption (no approved drugs in AML CR2, GPS will become standard of care - strong likelihood of being used in CR1 setting; not to mention WT1 is overexpressed in a variety of other cancers. The WT1 protein is the #1 cancer antigen... platform potential beyond just AML treatment. Now factor in SLS009 value. \-modeled peak sales multiplied by a factor (4x - 8x is fair). Run some models and see where you end up. Keep in mind that GPS and SLS009 have the Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designations, which offer certain benefits, including exclusivity/patent protection. For me, and my analysis, 10B is the floor, and 25B is not an impossibility. If you have never seen a bidding war scenario in the disclosure documents after all is said and done, the bids can go quickly! Ultimately, anyone investing has to dperform their own DD...

blazob

"REGAL (NCT04229979) is a Phase 3 randomized registrational clinical trial for GPS in AML patients who have achieved complete remission following second-line salvage therapy (CR2 patients)" Clinical trial is actually perfomed on patients that achived second remission with other therapies. This is not used as the first therapy in this clinical trial.

LiquidSquids

Typically BO occurs after results. Results were expected in Dec. Company had promised FA was likely in Dec. Company provided update that we are actually a ways away from trial completion. (80 events) 60 events Dec 2024, 72 events Dec 2025, 1/month. Once you understand the trial timeline and typical outlook for CR2 AML patients you start to realize it's probably lasting longer for a reason and that is their drug is working very well. Big Pharma can put this timeline together too. Big Pharma can typically only convince their board of say a 300% premium on stock price for a BO. If they're willing to take a risk on this timeline math (technically anything could happen bc the trial is still blinded but they know it's a likely success) they could extend a BO offer before trial completion (expected in August at earliest.) If the company has a concrete buyout offer that's say way more than 300% premium at current value, the powers that b COULD leak some info to the market makers and walk the stock price up to a buyout offer worthy price at any time.

SilentExtinction

shots of CR 18 for all of you guys if you find a way to stop your orange regard from having annexation wet dreams.

le_pedal

what crossover besides subaru/audi has the best AWD system? I saw a video of an AWD CR-V and it was absolutely useless on a roller test.

halfbreed22000

Saulsbury energy in texas has been dumping loads of money into trump's campaign. Ironically CR "Bubba" Saulsbury has a long connection to trump since he was a child and, when Bubbas dad ran the company

AverageUnited3237

They're getting amazing results and extending the mOS to 25+ months for AML CR2, that's a tripling of the lifespan under the best available therapy. Lots are living 30+ months

HatNo9667

I have a friend a PhD that works in the space and here is what they said to me: Galinpepimut-S + GM-CSF is similar to PR1 Peptide vaccine. It will induce immune response, such as antigen specific CD4/CD8+ T cells but likely limited CR, because patients with AML don't have enough T cells. They will get good results though, if they preselect patients with low blast and active T cells.

bannedbutunforgotten

I wish GPS would be approved already so it can cure this cancer of a "DD" post. Full of half-truths and lies. I don't believe someone is this god awful at "DD" so I have to assume you're a short who got caught with their pants down. There is way, way too much to dismantle so I'll go about one of the half-truth and one of the full lies: true GPS is not Keytruda, \_yet\_, but Keytruda started with 1 indication and now has 40. A drug/treatment needs to start somewhere then is branched out to other areas it can treat. GPS is not targeting one cancer type, GPS can treat ANY cancer with the WT1 protein, including solid tumours as demonstrated by multiple P1 and P2 trials. The FDA recommended CR2 for the P3 GPS trial as the \_fastest route to market\_ AND against a cancer that has 0 treatment options at this phase, not because GPS didn't show efficacy in other cancers. You had 5 years to short this bud. I don't think the right time was after the trial passed 4 futility tests, had its dosing changed twice and finally to ad infinitum, or 21 months after the final enrolment of the last 20 patients for a cancer that has a median OS of 5-8 months (12 month survival maximum as a "rare outlier" described by the top 4 doctors in the field) for a trial that was expected to hit its 80th events over 6 months ago. I have no clue where share price is going in the near term - no one does. But it is clear in the next 4 - 12 months that this stock will be firmly in the double digits and is a clear buyout target from several BPs who are facing a patent cliff. And everyone know this - AbbVie just moths ago terminated three separate trials where they were using their BAT against AML CR1 and CR2 due to futility. Hmm... so BAT has once again, and three times over, shown futility against this cancer type (against healthier cohorts mind you), and we have a trial here where patients are going on their 3rd and 4th years of survival for something with a well documented median OS of 5-8 months. Hmmm... and a phase 2 trial that demonstrated 5.4 median OS for BAT and a 21 median OS for GPS \_before\_ ad infinitum, with a p value of 0.02. HHHHMMMMMMMMMM. Biopharamas are inherently risky, but if you can't see how SLS has been derisked as much as you can possibly dream for, there is no helping you and you should just go to the casino since your performance in the market will be dictated by random forces anyway.

Due_Citron4079

I don’t disagree with some of the points that you’ve made, but I also look at this through a slightly different lens. First, on BAT survival: if the claim is that AML patients in CR2 who are transplant-ineligible now achieve 10–12 months median OS on BAT, and that figure is being used as a base-case assumption in your HR analysis to determine a probability of success for the trial, that really needs a clean, apples-to-apples citation or reference in the maintenance-from-CR2 setting with OS measured from randomization. Absent that, the commonly referenced benchmarks for this population remain in the single-digit month range, and is still widely referenced in the hematology community. Obviously, small sample sizes can produce distortions, but a 10–12 month median OS for BAT would be unprecedented in this setting and, in my view, should be treated as a stressed case from an analysis standpoint, not a base case. Second, on interpreting the event dynamics: I agree they’re not a smoking gun. But calling a sustained post-interim slowdown in events “statistically worthless” overstates the case. It’s directionally positive, particularly given that prior Phase 2 data showed a late-forming survival tail in the experimental arm. I fully agree the study is blinded and that the tail could theoretically be attributed to BAT because we just don’t know yet. My argument is simply that it’s more reasonable to expect Phase 3 to track closer to observed Phase 2 behavior than to assume BAT outcomes that would contradict both historical data and consensus amongst hematology experts for this patient cohort. Finally, on dilution and buyout: if Phase 3 fails, they’ll further dilute to focus on SLS009, no argument there. But if Phase 3 succeeds, history suggests these assets are far more likely to be partnered or acquired than slow-walked through multiple fully diluted trials. Large pharma with global infrastructure prefers to run commercialization end-to-end rather than leave it to a tiny standalone organization. A buyout is made more likely by the 2029 patent cliff, where large pharma needs de-risked assets to protect forward revenue, which is a major tailwind for biotech M&A over the coming years. AbbVie, in particular, would have reason to care if a competitor like Pfizer or Merck for example acquired a validated Phase 3 asset with platform potential in other areas where the WT1 antigen is prevalent, and encroaching on their market share within AML. I’m not claiming this meets its primary endpoint with 100% certainty. I’m saying the bearish case overstates how “settled” BAT improvement is, while understating how quickly the strategic calculus changes if Phase 3 is positive. I personally took a large position in early December when the stock was in the $1.50-$1.60 range after tracking this name for months (1,500 calls with varied expirations ranging from 1/26 - 1/27 with $2.5-$3.0 strikes) I took the insider purchase of 60,000 shares in November to validate my directionally positive thesis on the trial and felt comfortable with the risk given the asymmetric upside at that point in time.

JiiJiiRoman

AML Initial Diagnosis BAT is either a fixed duration or continuous therapy. If complete remission is achieved, patients usually survive for 18-24 months with gruelling side effects of the currently best available drugs. Should the AML relapse and CR2 be achieved, the life expectancy is grimly months, not years. GPS has proven to boost overall median survival to >60 months in first line, which was 18-24 months previously with current standard of care. 21 months in second line with GPS, comparatively less than a year with current standard of care. It’s important to note that the median overall survival (mOS) is estimated to be 6-8 months in patients who do not receive transplant in CR2. Transplant is NOT allowed in REGAL patients after CR2 and before enrollment. Transplant is the only potentially curative treatment for most AML patients, but only about 40% of AML patients can receive a transplant; approximately half of transplanted patients are cured but, even then, the patient can experience a relapse. Should a relapse happen on HMA+ventoclax combination, (the current standard of care), the survival is only about 2.5 months. Survival remains limited in patients who achieve response. GPS maintenance HAS PROVEN in earlier trials to significantly prolong survival. >60 months in first line patients in remission. 21 months in second line patients in remission. The longer the duration of REGAL phase 3, the more likely it is that the numbers will match previously done trials, if not blow them out of the water with even better results. Multiple cancers express WT1, but in AML it is more than a 95% expression. It is an over expression. GPS is an off the shelf drug, not patient specific. It is easy to administer, with no known harmful side effects aside from local reactions. It is a subcutaneous vaccine that can, with collected trial data, be administered ad infinitum with, let me repeat, safe to date the only known side effect to be a local reaction (subcutaneous injections might cause irritation around the skin where the injection administered).  Look, I could write even more, and to anyone who has read this post; I urge you to, if you haven’t yet, research into SLS. All of the above information is from last October’s virtual R&D Day. It is 2 hours long, with great slides filled with data. And doctors with actual clinical experience. GPS could be the first in class & best in class AML treatment. I think every single point of OP’s can be broken down and explained scientifically with data to back it up. It’s just a huge wall of text, pointless garbling. Even if it were to be true and GPS somehow fails; would you not want to dream big? What GPS could potentially achieve is nothing short of groundbreaking. Think of the physicians who have to break the news to their patients, that their life expectancy is months should they receive the standard of care treatment. With GPS, it could be years. It could be a monumental vaccine.

TruthSleuth709

There is no doubt that with some vyvanse, Ritalin, ketamine, and an amateur background in statistics: this guy knows better about clinical trials study design than Thomas Fleming. The biostatistician who developed THE method for statistical analysis of this type of trial and designed the SLS REGAL trial as a member of the IDMC. [https://ir.sellaslifesciences.com/news/News-Details/2020/SELLAS-Establishes-Independent-Data-Monitoring-Committee-of-Leading-Clinical-and-Biostatistics-Experts-for-Pivotal-Phase-3-REGAL-Clinical-Trial/default.aspx#:\~:text=Thomas%20Fleming%2C%20Ph.D.,%2Dleukemic%20therapy%20(CR2)](https://ir.sellaslifesciences.com/news/News-Details/2020/SELLAS-Establishes-Independent-Data-Monitoring-Committee-of-Leading-Clinical-and-Biostatistics-Experts-for-Pivotal-Phase-3-REGAL-Clinical-Trial/default.aspx#:~:text=Thomas%20Fleming%2C%20Ph.D.,%2Dleukemic%20therapy%20(CR2)). https://preview.redd.it/7eiuc2kv05bg1.jpeg?width=1080&format=pjpg&auto=webp&s=1a22db3f75ef43ae12d5e55dcfcc81ff3c77decc

Sensitive-Radish-292

**Ad last paragraph)** This is the one argument that I'm excited about the most, because it actually provides something "more tangible" than the keytruda 2.0 argument. And yet again it's also wrong, because it doesn't threaten the V+A treatment, mostly because (as far as I understand) V+A is used to get the patient into remission and GPS is used as maintenance. So you can't really use the 2.5B business, because it will still be used in this case - it doesn't get replaced. Yes I've read that it can be used for maintenance as well, but the way it's being administered is what makes it so expensive in the first place. **BUT** Let's assume that's correct (that's the mathematician in me speaking, sorry for boring you) and say that GPS is worth the 2.5B then. Given the fact that you're talking about a new trial -> it will require more another trial, which can easily be another ±70-100M (given the fact that the current one lasted almost 2 years and assuming the current cash burn) as well as additional trials, manufacturing ramp up etc. Now let's look at current outstanding shares and the total outstanding if warrants are executed: 200M outstanding (an increase by 34% roughly) giving them maybe 50-60M± (strike prices at 1.88-2.00 IIRC) which is not what they want/need, because there is like 4M warrants priced at $5.20 ... and that's where you get fucked over by the warrant inducement program. Because in order for them to exercise those warrants the price of the stock would have to reach more than $5.2 if it doesn't and they need the cash they will have to order cheaper ones which won't be easy if about 45M warrants were already issued at 2.00 (I just don't see an institutional investor agreeing to something like 4). This alone will drive the price down back to the <$3 range. Since they won't be able to make profit from the drug until its manufacturing is ramped up (can easily cost an additional 50M+) your only chance is truly a buyout. If we then take the same logic we took for CR2 and apply it for CR1 we will only double the money that I hinted to in the post. And by the time all this is done you will be looking at another 50-100M shares added to the total outstanding. So where will that leave you? Do you really believe that their Mkt Cap will keep on increasing? You are playing with fire because you are betting on the fact that this drug will OUTPERFORM (positive event) vs SAME EFFECT / UNDERPERFORM (negative events) ... AND ... they won't get ANY bad news with their CDK-9 stuff which I want to remind you - so far most of the CDK-9 stuff (IIRC) had a lot of negative effects or required special conditions to be met with patients.

Odd-Public-8544

Their "secondary" drug SLS009 is worth $10.5bn to Abbvie alone as it beat Ventoclcax like a red headed step child in a Phase 3 trials. Ventoclcax makes $abbv over $3bn in revenue. 3.5x P/S. GPS could have peak sales on par with Keytruda of $20+ bn plus if it expands into other WT1 cancers. Even in AML alone it's worth $5-6bn of sales by 2028 for all CR1 and CR2 patients. That makes a buyout of $25bn for the duo likely. But I'll take anything above $16bn

Ih8chiggas

A bit of researching and you will see for yourself the nature of drug trials: Source: [National Library of Medicine](https://clinicaltrials.gov/study/NCT04229979) "Patients on the BAT arm may be treated with 1. observation (whereby palliative management with hydroxyurea is allowed), 2. a hypomethylating agent (decitabine or azacitidine), 3. venetoclax and/or 4. low-dose ara-C. Patients whose remission in CR2 can be maintained with molecularly targeted agents (e.g. FLT-3 or IDH inhibitors) per investigator's determination will not be eligible. However, there are no restrictions on prior use of any agents in the CR1 setting. Patients cannot receive GPS as an adjunct therapy to any other agents." In my own beliefs I do not think it's ethical to force placebo treatments on anyone if they can potentially get a life saving drug instead, but here we are. I'm absolutely not shilling since I'm making money off of it and everybody who does this risks capital? It's called investing

Due_Citron4079

I’m not sure where the 10–12 month median overall survival figure for modern AML CR2 transplant-ineligible patients is coming from, because there isn’t a single study that supports that number. In this trial, it’s possible the BAT arm could land in the 10–12 month range due to small sample size, but anything above 12 months would be unprecedented. Even 11–12 months would already be pushing the upper bound of historical survival data for this population. The main takeaway from the most recent PR is the event dynamics. As of 12/26/25, the trial has incurred 72 events. The 60th event occurred on 12/10/24. That means the event rate has collapsed to <1 event per month, which is exactly what you see in oncology trials when a survival tail forms in one arm. It’s extremely unlikely that this tail is coming from the BAT arm. The IDMC recommended “continue without modification” in August 2025. If the control arm were unexpectedly developing a survival tail, the trial would have been stopped for futility at that point. The Phase 2 data already showed a late-forming tail in the GPS arm with a median OS of ~21 months, and it’s far more plausible that Phase 3 is tracking closer to the Phase 2 than that BAT patients suddenly experiencing a medical miracle. I’ve also seen the “Keytruda 2.0” argument floated, which I think is insanely unrealistic. The real bull case is much simpler: if Phase 3 hits its primary endpoint, GPS expands into CR1, which is roughly 10x the TAM of CR2. At that point, GPS directly threatens AbbVie’s Venetoclax franchise, which does ~$2.5B in annual revenue. SLS is obviously not commercializing this alone. The most likely outcomes are either a partnership with big pharma or an outright acquisition. I think defensive M&A by AbbVie to protect Venetoclax make the most sense, but another big pharma player could swoop in to expand into AML and try to take Abvie’s market share.

Over_Bluebird

28% short of float... 40 million shares... Effacicy looks so good that Chief Medical officer had to re-adjust end of trial date twice... First from August 2025 to December 2025 and at the end of December he had to excuse himself again because patients are not dying at the rate as expected... They live longer and the question is whether they will have to halt the trial because the patients stay alive... If it wasn't a serious matter it would have been hilarious... These are cancer patients with AML CR2 which normally don't live longer than 5 to six months but some are on the trial for multiple years since 2021... They say that GPS has turned the cancer into a chronic disease which means that as long as patients get a monthly vaccine their immune system can handle AML CR2.... The shorts here bet on the wrong stock because the company is worth billions and the drug effacicy path is highly likely effective for 20 other cancer types!!!

Yung_Ceejay

Absolutely. The P2 was supposed to be a pilot trial but AML CR2 patients lived for times longer with p=0,0175 so the FDA upgraded it to P2 if you will! These patients living 21 months were sicker than P3 with all MRD+, didn't receive ad infinitum dosing and had a lower rate of immune responses than P3 at IA so it's safe to say that REGAL will exceed 21 months.

Yung_Ceejay

Appreciate your feedback. I am not in the slightest bit concerned about Onureg/ oral Aza. The QUAZAR AML trial that led to oral Aza maintenance being widely used has serious limitations most notably patients receiving sub-standard consolidation and rescue therapy. The maintenance therapy replaced consolidation for these patients! Vinay Prasad wrote a paper picking https://pmc.ncbi.nlm.nih.gov/articles/PMC9198931/ Not only is the whole rationale behind Aza maintenance flawed, using a cytostatic for extended durations leads to accumulating toxicity and emerging resistance. GPS represents a massive paradigm shift and produced far better results than onureg in previous trials. 67+ months in CR1 vs 24 in Quazar CR1. 21 months in the Moffit trial with MRD+ patients in CR2... These are small trials so we need REGAL data but the higher rate of immune response, infinite dosing and MRD- patients being enrolled suggests that REGAL GPS mOS in CR2 will blow Onureg CR1 survival out of the water. Quazar-AML is also flawed in assessment of quality of life as the QOL data was collected when the patients were actually off treatment right before receiving their next dose. GPS should show dramatically increased survival and quality of life compared to AZA.

Yung_Ceejay

Thats wrong. Venetoclax improves survival by getting people into remission but there is zero data showing improved survival as a maintenance agent. KOL cited the mean duration of response for the AVALON VEN/AZA of 7,6 months as a surrogate for the duration of relapse free survival in VEN/AZA responders. Also according to the paper by Jamy et al. BAT will roughly be evenly distributed across the strata so only roughly 25% of BAT should even receive VEN/AZA. Venetoclax can produce durable survival in patients with NPM1 or IDH without co-occuring high risk mutations but IDH is targetable so these patients are excluded from REGAL. The only maintenance trial that ever showed increased mOS was QUAZAR AML, the trial that led to Azacitidine being widely used in CR1 maintenance. QUAZAR-AML had some pretty serious methodological flaws, Vinay Prasad wrote a paper picking it apart. https://doi.org/10.1182/bloodadvances.2021006857 Don't come at me with the MDACC trial maintaining AML patients in first remission. These are patients with low risk cytogenetics who are expected to do well with observation, high rate of CBF-AML, low age, low ECOG. It's too small to extrapolate anything about VEN/AZA maintenance increasing survival. Only data that came off it is VEN working best with NPM1/IDH. https://pubmed.ncbi.nlm.nih.gov/38548404/ BAT might very well be at 12 months mOS but not because of VEN/AZA. Hawthorne effect and immortal time bias play a much larger role than VEN/AZA.

mad_papooser

Solid summary. I own 28k common shares and 1300 contracts in leaps so I am bullish. Just to critique, you said “the fact that none of the other available BAT drugs have demonstrated improved survival” is inaccurate. The 6-8 mOS for the BAT arm that is often quoted is from very outdated data prior to venetoclax and HMA use in this CR2 population. I think this trial will be a win when it’s all said and done, but I do think that the BAT arm has a very likely outcome at 12-14 months + for the mOS. Going to be a looooong half a year or more to see this thing through.

biotechinv21

There is no placebo group in ph3 cancer trial. Listen to the 10/29 KOL CC to hear how poor the outcome is for AML CR2 patients.

Motorbarge

Here are some quotes from chatgpt: * **Without effective maintenance:** CR2 AML patients usually relapse and succumb within \~6–8 months historically after remission. * **With modern BAT (including venetoclax combinations):** Survival may be somewhat longer but still suboptimal. * **REGAL’s pooled interim data suggest survival far beyond historical expectations**, signaling that *something is happening* in the trial arms that’s extending life compared with old benchmarks — a key reason investors view the final OS readout as a major catalyst. # Real-World Takeaways (Benchmarks) |Population|Typical Historical Median OS|Notes| |:-|:-|:-| |**AML CR2, no transplant, older SOC (\~pre-venetoclax)**|\~5–7 months|Based on older Phase 2 and retrospective data.| |**AML CR2 with modern BAT (e.g., venetoclax + hypomethylating agent)**|\~8–12 months\*|Literature and community commentary suggest improved—but still poor—survival. | |**REGAL pooled interim survival**|\>13.5+ months|Trial median survival not yet reached at \~13.5 months follow-up — suggests better outcomes than historical SOC|

GeoLogic23

Looks like some insider selling at GTI from President, Chair/CEO, and General Counsel. For [Ben](https://archive.fast-edgar.com/20251230/A92ST22C5222T2N2222322Y2GBELZ222A272/) and [Anthony](https://archive.fast-edgar.com/20251230/AVZZP22CR22282Z2222U22ZZMLFKZ26I9B72/) it says they sold like $2M worth of super voting shares? [General Counsel](https://archive.fast-edgar.com/20251230/A3ZK222CZ222E2Z2222H22ZZVTTHZPGSB272/) sold about $160k.

ThrowRAkakareborn

CR7 on the next cover, my camel returns!!!!

OddMove2382

LOL. Teslas have never been recalled for FSD issues. The AI is constantly being upgraded. The latest 14.2.1.25 is point to point amazing. You clearly have never been in a Tesla. Morgan Stanley analyst finds Tesla FSD "game changer" after 1,400-mile trip. https://share.google/hKVa0WozNRVI8SN6V Piper claims Tesla’s FSD is ’probably already better’ than most U.S. drivers. https://share.google/98mT633ruqgesg1CR

Locus_In_Quo

# Yes, a government shutdown in 2026 is a strong possibility, as a November 2025 stopgap measure (Continuing Resolution - CR) only funds most U.S. agencies until #January 30, 2026, setting up a potential renewed funding crisis for early 2026 unless Congress passes full-year appropriations or another short-term fix. The current situation is a temporary patch following a record 43-day shutdown in late 2025, with major disagreements over spending levels, policy riders (like ACA subsidies), and the budget for Fiscal Year 2026

yeahyoubored

didn't the CR just basically ban HEMP tho....

JG_Wentworth_877_

It did receive the official approval today. https://docs.oversightboard.pr.gov/n/id6ek3qs8yrm/b/CR_PUBLIC/o/6877_PREPAandNFEnergia,LLC(MultisiteLNGSalesAgreement)(December2025).pdf

squirrelysupra

https://preview.redd.it/btmsb52o085g1.jpeg?width=1486&format=pjpg&auto=webp&s=921b8c2f29c508168bc9702679de184ee3e86712 [https://docs.oversightboard.pr.gov/n/id6ek3qs8yrm/b/CR\_PUBLIC/o/6877\_PREPAandNFEnergia,LLC(MultisiteLNGSalesAgreement)(December2025).pdf](https://docs.oversightboard.pr.gov/n/id6ek3qs8yrm/b/CR_PUBLIC/o/6877_PREPAandNFEnergia,LLC(MultisiteLNGSalesAgreement)(December2025).pdf) FULL APPROVAL!

CryptoApeNL

It’s approved https://docs.oversightboard.pr.gov/n/id6ek3qs8yrm/b/CR_PUBLIC/o/6868_PREPAandNFEnergia,LLC(MultisiteLNGSalesAgreement)(November2025).pdf?_gl=1*1ehsgwg*_ga*MTI3NTQxNTc5OC4xNzYyMjA1MTYz*_ga_LVK7G3FFVG*czE3NjQ0MTY4NTQkbzExJGcxJHQxNzY0NDE2ODY1JGo0OSRsMCRoMA..

Happy_Discussion_536

He won't bargain anything. Just ask for a CR and he'll get it.

four_twenty_4_20

>but if that were the case they would have outlawed all cannabis in the ‘must pass’ CR, not just hemp THC. Cannabis is already federally illegal as an S1 substance...

HugeDramatic

I can’t believe it only took ~9 days to walk some of these stocks back down to near all time lows. It made sense to me when the 2024 FL recreational cannabis amendment failed since so much hype had been built up on it and the bubble popped…. This time I don’t get it at all. Hemp is literally the number one competition for state regulated cannabis and the government just shut the door on that. Maybe the sentiment is that the republicans are heading more towards general prohibition with that move… but if that were the case they would have outlawed all cannabis in the ‘must pass’ CR, not just hemp THC.

Inventor141

Starting to look worrying? Since October, underestimated idiots not passing clean CR due to insane level of TDS in Senate. Cost us all, big $.

modder9

Oh you haven’t heard about what snuck into the CR…

Level_Society1459

Dude I am a dem let's be realistic I don't care who is in charge we all know they are not gonna support next CR Let's be real It's about our $$$ and his to manage

Aetch

Did you not see the CR that was passed?

UsedState7381

Apparently, canna Twitter has found out the reason for the dump today. https://x.com/HenryLuMencken/status/1989477502595600625?t=BIpejAiyfCgy3kYGDudAFQ&s=19 Or rather, they believe that the posts(there was a bunch of them today, I tried to reply to one before the poster deleted it) about this bill circulating around the social media that would stop the rescheduling process, is the reason for the crazy dump at close. The bill does exists, but the allusion that this was voted in the CR is completely fake, this has not been voted yet and is likely to fail again. I would not be surprised at all if it was the hempsters pushing this shit forward. ...Man, I just wanna get off this train already 😭 

unclefire

Rates aren't necessarily coming down. Missing data + inflation still being a threat. Budget situation isn't settled either-- CR is just for a few months. Budget overall is still a mess with high deficits. ACA, medicaid, etc. are still huge issues. There are tons of layoffs happening.

PlasticBreather

The fact that Republicans are happily cutting things we've paid taxes into for years, giving themselves literal millions in the most recent CR, holding our most vulnerable hostage with SNAP, etc etc. 35% of SPY is 7 companies sending money back and forth.

manualCAD

It's funny how it is framed like it's a standalone bill and not a small rider on a massive CR to reopen the entire US government

TheSmokingLamp

Congrats! Your bags are about to be even heavier after they slipped in anti-cannabis portion to the CR for re-opening the government!

Proper_Look_7507

And let’s Senators sue for $500k for their phone records being tapped. But it’s definitely a clean CR and nothing was added or changed

SpyBagholder

Wait so they vote to veto the CR right? So this next vote is YEA to veto or NAY to not veto right?

LarryStink

Is the epstein vote part of the CR vote to end shutdown or is it separate?

FJB69420

All democrats had to do for 5 weeks was sign a clean CR and then negotiate while the government stays open lmao

Bazzer82

Honda CR-V 2014 but all paid off and is reliable and spacious.

Low_Plastic363

Priced in. If they don't pass the CR though... look out below. 99% chance they pass it.

CapitalBias

"we refused to pass the CR and furloughed the BLS for the month" "what do you mean there's no report for the month??" - redditors itt

Wonderful-Smoke843

This is everyone in the house selling before they announce they will not pass the CR

gopoohgo

Sup degens.   Say goodbye to your mail order hemp-derived THC from the Farm Bill loophole.   That was closed in the Senate CR and will probably pass the House as well

Icy-Profession-6068

Sorry I don’t think I explained well enough. For example, Yesterday afternoon 1:15pm when spy was just under 680 I bought a 680 call (0.58) and sold a 681 call (0.22) against it for a $36 DR. (Debit Spread), That way my break even moves down in exchange for limited downside but I personally want a small consistent gain on my 0dtes not a 5x, so I’m ok with limiting my upside if it limits my downsides. I like to believe it improves my expected value per trade but honestly I haven’t been doing it for long enough. Spy closed well above both, I closed a little bit early for a $85 CR. Could’ve waited but spy does get really volatile before closing.

EpiphyticOrchid8927

CR has not passed the house and signed by president yet

wafflepiezz

$GOOG $GOOGL calls continue to print New ATH’s probably tomorrow, on the biggest Germany investment announcement https://finance.yahoo.com/news/google-announce-biggest-ever-investment-095210905.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAADxS3yPWCFpHb74X1ypEm6R6Zp-dQHZbCow9PImmUXOQKibzuSpeRgdrsZXp8C6VQxVvmlfud0-MdRDiVT-IsnbgWyNgJXcC-M-STK_eRgtmo1G6fdgps3ETPGpoYbWNAzPgeUbbkzsRYwrum0eFTaH8CR0MplAf5k1cOHyvWJWt

Living-Stomach-2079

But to go back to the original point. Trump PROPOSED giving money to people. He WANTS to. But, please tell me... Who has the power of the purse? And since you know that's not Trump , how many votes would a new spending bill need to pass so people could get that money he wants to give out? They would need 60 votes. It just took 42 days to get 8 Dems to vote yes to fund the government with their own CR. Do you REAAAAAALLY think the Dems are gonna vote yes to a stimulus check and make trump look good after just being willing to starve the poor to try to get power? Like you have to be a special kind of stupid to sit here and make fun of trump for suggesting it instead of mad at the Dems for obstructing it for political games. Again, has trying to help people. Dems do not care. They want power at any cost

AutisticcPengiun

watch the House not pass the CR. algos gonna go crazy

Living-Stomach-2079

Again, like I said. Clearly impossible. Please, tell me again how many votes were needed to pass BIDEN'S CR THAT THEY'VE BEEN PASSING FOR NEARLY 3 YEARS? It wasn't Republicans that held America hostage to demand 1.5 trillion in spending for illegals and liberal projects that got shut down because THAT'S EXACTLY WHAT WE VOTED FOR. Multiple Democrats literally went on TV and called the poor "leverage" you dumb shit. And now the left is mad that their leverage is gone. That LITERALLY MEANS THEY ARE MAD POOR PEOPLE WILL HAVE FOOD. Trump didn't cause this. It's amazing the mental gymnastics you have to do to even say that dumb shit

GeoLogic23

Like Ben stopping investor calls and then Ben and the President of GTI starting to sell shares? [https://archive.fast-edgar.com/20251110/A922H22C5222R2N2222322Y2QAOLV222A272/](https://archive.fast-edgar.com/20251110/A922H22C5222R2N2222322Y2QAOLV222A272/) [https://archive.fast-edgar.com/20251110/AVZON22CR22272Z2222922ZZWL3KZ26I9272/](https://archive.fast-edgar.com/20251110/AVZON22CR22272Z2222922ZZWL3KZ26I9272/) "These shares were sold in multiple transactions at prices ranging from $6.50 to $6.55, inclusive."

MmNicecream

Schumer actually seems to have been against the passage of the CR, and Dems who voted for it did so against his wishes. So, for once, he's not being a doormat for the Republicans. Instead, he just can't manage to keep his party in line.